Kurin, Inc. Receives Allowance from United States Patent and Trademark Office of Additional Claims to its Innovative Blood Culture Collection Device
SAN DIEGO--(BUSINESS WIRE)-- Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the United States Patent Office allowed its patent application and has issued U.S. Patent No. 10,827,964. The Kurin blood culture collection set is a replacement for traditional collection sets, enhanced with technology that sidelines skin contaminants while preserving the standard blood culture collection technique for clinicians.
"We continue to add to our intellectual property portfolio for our unique Kurin product line," said Bob Rogers, Inventor and Chief Executive Officer. “We have been pleased with the rapid acceptance of Kurin in the marketplace, as hospitals continue to demonstrate interest in addressing the significant financial and clinical problems caused by contaminated blood cultures. This US patent further strengthens our position in the market. The simplicity of Kurin is critical to caregiver compliance and compliance is the key to improving clinical outcomes. With no need for manual manipulation, a Kurin set makes it effortless for clinicians to incorporate new technology into their routine collection process.”
Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection—simply better than conventional diversion. Contaminated blood cultures are a significant problem, as roughly one-third of positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005004/en/
Source: Kurin Inc.
View this news release online at: